How to De-Risk Complex Molecule Formulation

Posted: 06/07/16

If formulation problems surface late in the process of turning active pharmaceutical ingredients (APIs) into beneficial drugs, developers may have to change their API production processes, and, in the worst cases, redo Phase I and Phase II trials Anil Kane, Global Head of Formulation Sciences at Patheon, a leader in contract drug manufacturing, explains how developers can anticipate formulation problems in an article we helped him publish in BioProcess Online, here.